Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN: 2,002 Adverse Event Reports & Safety Profile

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit
2,002
Total FAERS Reports
79 (3.9%)
Deaths Reported
265
Hospitalizations
2,002
As Primary/Secondary Suspect
30
Life-Threatening
57
Disabilities
Merck Sharp & Dohme LLC
Manufacturer

Drug Class: Actively Acquired Immunity [PE] · Manufacturer: Merck Sharp & Dohme LLC ·

First Report: 1990 · Latest Report: 20250925

What Are the Most Common VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN Side Effects?

#1 Most Reported
No adverse event
772 reports (38.6%)
#2 Most Reported
Product storage error
330 reports (16.5%)
#3 Most Reported
Drug ineffective
245 reports (12.2%)

All VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
No adverse event 772 38.6% 0 0
Product storage error 330 16.5% 1 0
Drug ineffective 245 12.2% 4 45
Herpes zoster 209 10.4% 9 39
Diarrhoea 135 6.7% 2 37
Nausea 133 6.6% 0 27
Drug intolerance 125 6.2% 0 17
Expired product administered 125 6.2% 0 2
Pruritus 119 5.9% 0 22
Pyrexia 119 5.9% 11 37
Hypersensitivity 109 5.4% 0 23
Pain 105 5.2% 16 37
Vaccination failure 102 5.1% 10 26
Lymphoma 101 5.0% 0 1
Off label use 99 5.0% 2 39
Alopecia 97 4.9% 0 3
Neoplasm malignant 97 4.9% 0 1
Rash 97 4.9% 3 41
Tooth loss 96 4.8% 0 2
Onychoclasis 94 4.7% 0 1

Who Reports VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN Side Effects? Age & Gender Data

Gender: 54.9% female, 45.1% male. Average age: 39.7 years. Most reports from: US. View detailed demographics →

Is VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN Getting Safer? Reports by Year

YearReportsDeathsHosp.
2000 1 0 0
2002 1 0 0
2004 1 0 0
2005 3 0 1
2006 2 0 0
2007 2 0 0
2008 1 0 1
2009 8 2 2
2010 5 3 3
2011 7 1 3
2012 13 0 4
2013 22 1 11
2014 44 3 13
2015 74 4 14
2016 86 12 15
2017 381 16 24
2018 129 2 20
2019 161 1 6
2020 45 1 3
2021 44 0 16
2022 53 2 2
2023 48 0 11
2024 44 2 6
2025 123 0 10

View full timeline →

What Is VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN Used For?

IndicationReports
Prophylaxis 1,444
Product used for unknown indication 270
Immunisation 123
Routine health maintenance 49
Rheumatoid arthritis 38
Varicella immunisation 34
Herpes zoster 26
Herpes zoster immunisation 5

VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs Alternatives: Which Is Safer?

VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VASOPRESSIN VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VECTIBIX VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VECURONIUM VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VEDOLIZUMAB VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VELAGLUCERASE ALFA VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VELCADE VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VELETRI VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VELIPARIB VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VEMURAFENIB VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN vs VENETOCLAX

Other Drugs in Same Class: Actively Acquired Immunity [PE]

Official FDA Label for VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN

Official prescribing information from the FDA-approved drug label.